PartnershipApr 21, 2026, 04:22 PM
Rigel Pharma: Eli Lilly Terminates Ocadasertib Collaboration
AI Summary
Rigel Pharmaceuticals announced that Eli Lilly and Company has elected to terminate their License and Collaboration Agreement, effective June 15, 2026. This agreement granted Lilly exclusive worldwide rights to develop and commercialize ocadusertib (R552), a RIPK1 inhibitor, for non-CNS and CNS diseases. Rigel expects to regain full rights to the licensed compounds and related programs upon termination and will no longer receive future milestone payments or royalties under the agreement.
Key Highlights
- Eli Lilly terminated License and Collaboration Agreement with Rigel.
- Termination effective June 15, 2026.
- Agreement covered ocadusertib (RIPK1 inhibitor) for non-CNS and CNS diseases.
- Rigel expects to regain full rights to licensed compounds.
- Rigel will not receive future milestones or royalties from the agreement.